Fruquintinib DDI Study With P-gp and BCRP Substrates

NCT05368805 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Fruquintinib
DRUG: Dabigatran Etexilate
DRUG: Rosuvastatin

Sponsor

Hutchmed